+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Paroxysmal Nocturnal Hemoglobinuria Treatment Market - Global Forecast 2025-2030- Product Image
Paroxysmal Nocturnal Hemoglobinuria Treatment Market - Global Forecast 2025-2030- Product Image
Sale

Paroxysmal Nocturnal Hemoglobinuria Treatment Market - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 189 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 4968573
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market is undergoing significant transformation, driven by a surge in therapeutic innovation and evolving patient management strategies. This report offers essential insights for senior executives seeking to navigate, invest in, or optimize participation within the rapidly advancing PNH treatment landscape.

Market Snapshot: Paroxysmal Nocturnal Hemoglobinuria Treatment Market

The global Paroxysmal Nocturnal Hemoglobinuria Treatment Market grew from USD 3.49 billion in 2024 to USD 3.89 billion in 2025. It is projected to continue growing at a CAGR of 10.92% through 2030, reaching a value of USD 6.51 billion. Multiple factors, including next-generation complement inhibitors, expanded regulatory adaptability, and the broad adoption of precision medicine, are fundamentally influencing market development.

Scope & Segmentation

This comprehensive report analyzes the full spectrum of market dynamics, leading technologies, and regional diversity shaping PNH therapies:

  • Treatment Classes: Includes complement inhibitors (Eculizumab, Ravulizumab), innovative gene therapies (LentiGlobin Gene Therapy), and supportive therapies (blood transfusion, iron chelation therapy).
  • Administration Frequency: Encompasses every eight weeks and every two weeks dosing intervals, reflecting trends in patient adherence and care optimization.
  • Distribution Channels: Hospital pharmacy, online pharmacy, and retail pharmacy each support various stages of therapy access and continuity.
  • End Users: Care is provided across home care settings, hospitals, and specialty clinics, depending on patient needs and treatment complexity.
  • Routes of Administration: Intravenous and subcutaneous administration strategies are shaping patient autonomy and healthcare delivery practices.
  • Line of Therapy: First, second, and third-line options reflect evolving patient management and personalized dosing regimens.
  • Dosage Strengths: High, low, and standard dose variations address diverse clinical scenarios, including refractory cases.
  • Regions Covered: Americas (with granular analysis of the United States, Canada, Mexico, Brazil, Argentina), Europe/Middle East/Africa (United Kingdom, Germany, France, Russia, United Arab Emirates, and others), and Asia-Pacific (China, India, Japan, Australia, South Korea, and additional nations).
  • Industry Players Profiled: AstraZeneca plc, Apellis Pharmaceuticals, Inc., Swedish Orphan Biovitrum AB, Novartis AG, Genentech, Inc., Amgen Inc., and F. Hoffmann-La Roche Ltd.

Key Takeaways

  • Complement inhibitors have reshaped frontline treatment paradigms, with the introduction of longer-acting formulations directly impacting patient quality of life and care logistics.
  • Gene therapies are progressing, targeting not only symptomatic relief but also underlying disease pathology. Their emergence marks a promising pivot toward curative approaches for PNH.
  • Advancement in digital health integration now enables continuous tracking of hemoglobin levels and patient outcomes, supporting data-driven, adaptive clinical decision-making.
  • Distribution channels are increasingly aligned with patient convenience, as home-based and omnichannel strategies accommodate evolving treatment modalities and preferences suggested by senior leadership priorities.
  • Collaborations across pharmaceutical companies, research institutions, and contract manufacturers are accelerating clinical development and reinforcing global supply chain continuity.
  • Regional variations in reimbursement and healthcare infrastructure demand nuanced market entry and expansion strategies, with a focus on partnerships and tailored stakeholder engagement.

Tariff Impact and Supply Chain Adaptation

Upcoming United States tariff revisions for 2025 are anticipated to introduce cost pressures on key biologic imports crucial for PNH therapies. Companies are responding by diversifying procurement, optimizing risk pooling, investing in local manufacturing infrastructure, and leveraging contract manufacturing to sustain supply chain stability. Payer negotiations are evolving, with a shift toward outcome-based arrangements and reimbursement models that prioritize both affordability and long-term treatment adherence in this high-cost therapeutic category.

Research Methodology & Data Sources

This analysis leverages a robust, multi-source approach, including secondary reviews of scientific literature, regulatory documents, industry databases, and peer-reviewed journals. Primary research consisted of detailed interviews with global hematology experts, payers, and advocacy groups, ensuring contextual relevance and validation through data triangulation and expert review.

Why This Report Matters

  • Executives gain a comprehensive view of pivotal market drivers, shaping strategy and capital allocation for emerging and established therapeutic classes within the paroxysmal nocturnal hemoglobinuria treatment market.
  • In-depth regional and segmentation analysis supports informed decisions about market entry, partnership selection, and product strategy.
  • Tariff, reimbursement, and supply chain evaluations offer forward-looking perspective for risk mitigation and sustainable market positioning.

Conclusion

The evolution of PNH treatment depends on continuous innovation, adaptive strategies, and cross-functional partnerships. Executives leveraging these insights can align with patient needs, regulatory expectations, and commercial opportunities to achieve leadership in this dynamic market.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Emergence of complement C3 inhibitors targeting upstream complement activation in PNH patients with residual hemolysis
5.2. Increasing adoption of subcutaneous ravulizumab formulations to improve patient convenience and adherence
5.3. Development of novel gene therapies aiming for sustained PIGA gene correction in PNH bone marrow stem cells
5.4. Expansion of biomarker-driven personalized treatment strategies through high-sensitivity LDH and hemoglobin monitoring
5.5. Rising competition from biosimilar C5 inhibitors challenging incumbent monoclonal antibody pricing models
5.6. Integration of multifunctional bispecific antibodies targeting both C5 and C3 to enhance complement regulation
5.7. Growing focus on health economic outcomes research demonstrating long-term cost savings of early PNH intervention strategies
5.8. Advances in small molecule factor D inhibitors offering oral complement blockade alternatives for PNH patients
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Paroxysmal Nocturnal Hemoglobinuria Treatment Market, by Treatment Class
8.1. Introduction
8.2. Complement Inhibitors
8.2.1. Eculizumab
8.2.2. Ravulizumab
8.3. Gene Therapies
8.3.1. LentiGlobin Gene Therapy
8.4. Supportive Therapies
8.4.1. Blood Transfusion
8.4.2. Iron Chelation Therapy
9. Paroxysmal Nocturnal Hemoglobinuria Treatment Market, by Administration Frequency
9.1. Introduction
9.2. Every Eight Weeks
9.3. Every Two Weeks
10. Paroxysmal Nocturnal Hemoglobinuria Treatment Market, by Distribution Channel
10.1. Introduction
10.2. Hospital Pharmacy
10.3. Online Pharmacy
10.4. Retail Pharmacy
11. Paroxysmal Nocturnal Hemoglobinuria Treatment Market, by End User
11.1. Introduction
11.2. Home Care Settings
11.3. Hospitals
11.4. Specialty Clinics
12. Paroxysmal Nocturnal Hemoglobinuria Treatment Market, by Route of Administration
12.1. Introduction
12.2. Intravenous Administration
12.3. Subcutaneous Administration
13. Paroxysmal Nocturnal Hemoglobinuria Treatment Market, by Line of Therapy
13.1. Introduction
13.2. First Line
13.3. Second Line
13.4. Third Line
14. Paroxysmal Nocturnal Hemoglobinuria Treatment Market, by Dosage Strength
14.1. Introduction
14.2. High Dose
14.3. Low Dose
14.4. Standard Dose
15. Americas Paroxysmal Nocturnal Hemoglobinuria Treatment Market
15.1. Introduction
15.2. United States
15.3. Canada
15.4. Mexico
15.5. Brazil
15.6. Argentina
16. Europe, Middle East & Africa Paroxysmal Nocturnal Hemoglobinuria Treatment Market
16.1. Introduction
16.2. United Kingdom
16.3. Germany
16.4. France
16.5. Russia
16.6. Italy
16.7. Spain
16.8. United Arab Emirates
16.9. Saudi Arabia
16.10. South Africa
16.11. Denmark
16.12. Netherlands
16.13. Qatar
16.14. Finland
16.15. Sweden
16.16. Nigeria
16.17. Egypt
16.18. Turkey
16.19. Israel
16.20. Norway
16.21. Poland
16.22. Switzerland
17. Asia-Pacific Paroxysmal Nocturnal Hemoglobinuria Treatment Market
17.1. Introduction
17.2. China
17.3. India
17.4. Japan
17.5. Australia
17.6. South Korea
17.7. Indonesia
17.8. Thailand
17.9. Philippines
17.10. Malaysia
17.11. Singapore
17.12. Vietnam
17.13. Taiwan
18. Competitive Landscape
18.1. Market Share Analysis, 2024
18.2. FPNV Positioning Matrix, 2024
18.3. Competitive Analysis
18.3.1. AstraZeneca plc
18.3.2. Apellis Pharmaceuticals, Inc.
18.3.3. Swedish Orphan Biovitrum AB
18.3.4. Novartis AG
18.3.5. Genentech, Inc.
18.3.6. Amgen Inc.
18.3.7. F. Hoffmann-La Roche Ltd.
19. ResearchAI
20. ResearchStatistics
21. ResearchContacts
22. ResearchArticles
23. Appendix
List of Figures
FIGURE 1. PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2024 VS 2030 (%)
FIGURE 6. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY ADMINISTRATION FREQUENCY, 2024 VS 2030 (%)
FIGURE 8. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY ADMINISTRATION FREQUENCY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 10. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 12. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 14. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2024 VS 2030 (%)
FIGURE 16. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DOSAGE STRENGTH, 2024 VS 2030 (%)
FIGURE 18. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DOSAGE STRENGTH, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. AMERICAS PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. AMERICAS PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. UNITED STATES PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 22. UNITED STATES PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. EUROPE, MIDDLE EAST & AFRICA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. EUROPE, MIDDLE EAST & AFRICA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. ASIA-PACIFIC PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 26. ASIA-PACIFIC PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 27. PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 28. PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 29. PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET: RESEARCHAI
FIGURE 30. PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET: RESEARCHSTATISTICS
FIGURE 31. PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET: RESEARCHCONTACTS
FIGURE 32. PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY COMPLEMENT INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY COMPLEMENT INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY ECULIZUMAB, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY ECULIZUMAB, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY RAVULIZUMAB, BY REGION, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY RAVULIZUMAB, BY REGION, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY COMPLEMENT INHIBITORS, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY COMPLEMENT INHIBITORS, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY GENE THERAPIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY GENE THERAPIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY LENTIGLOBIN GENE THERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY LENTIGLOBIN GENE THERAPY, BY REGION, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY GENE THERAPIES, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY GENE THERAPIES, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY BLOOD TRANSFUSION, BY REGION, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY BLOOD TRANSFUSION, BY REGION, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY IRON CHELATION THERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY IRON CHELATION THERAPY, BY REGION, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPIES, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPIES, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY ADMINISTRATION FREQUENCY, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY ADMINISTRATION FREQUENCY, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY EVERY EIGHT WEEKS, BY REGION, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY EVERY EIGHT WEEKS, BY REGION, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY EVERY TWO WEEKS, BY REGION, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY EVERY TWO WEEKS, BY REGION, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 49. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2025-2030 (USD MILLION)
TABLE 51. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
TABLE 52. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2030 (USD MILLION)
TABLE 53. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 54. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 55. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 56. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 57. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY INTRAVENOUS ADMINISTRATION, BY REGION, 2018-2024 (USD MILLION)
TABLE 58. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY INTRAVENOUS ADMINISTRATION, BY REGION, 2025-2030 (USD MILLION)
TABLE 59. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY SUBCUTANEOUS ADMINISTRATION, BY REGION, 2018-2024 (USD MILLION)
TABLE 60. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY SUBCUTANEOUS ADMINISTRATION, BY REGION, 2025-2030 (USD MILLION)
TABLE 61. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 62. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 63. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY FIRST LINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 64. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY FIRST LINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 65. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY SECOND LINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 66. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY SECOND LINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 67. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY THIRD LINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 68. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY THIRD LINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 69. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
TABLE 70. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DOSAGE STRENGTH, 2025-2030 (USD MILLION)
TABLE 71. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY HIGH DOSE, BY REGION, 2018-2024 (USD MILLION)
TABLE 72. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY HIGH DOSE, BY REGION, 2025-2030 (USD MILLION)
TABLE 73. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY LOW DOSE, BY REGION, 2018-2024 (USD MILLION)
TABLE 74. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY LOW DOSE, BY REGION, 2025-2030 (USD MILLION)
TABLE 75. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY STANDARD DOSE, BY REGION, 2018-2024 (USD MILLION)
TABLE 76. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY STANDARD DOSE, BY REGION, 2025-2030 (USD MILLION)
TABLE 77. AMERICAS PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2018-2024 (USD MILLION)
TABLE 78. AMERICAS PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2025-2030 (USD MILLION)
TABLE 79. AMERICAS PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY COMPLEMENT INHIBITORS, 2018-2024 (USD MILLION)
TABLE 80. AMERICAS PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY COMPLEMENT INHIBITORS, 2025-2030 (USD MILLION)
TABLE 81. AMERICAS PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY GENE THERAPIES, 2018-2024 (USD MILLION)
TABLE 82. AMERICAS PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY GENE THERAPIES, 2025-2030 (USD MILLION)
TABLE 83. AMERICAS PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPIES, 2018-2024 (USD MILLION)
TABLE 84. AMERICAS PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPIES, 2025-2030 (USD MILLION)
TABLE 85. AMERICAS PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY ADMINISTRATION FREQUENCY, 2018-2024 (USD MILLION)
TABLE 86. AMERICAS PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY ADMINISTRATION FREQUENCY, 2025-2030 (USD MILLION)
TABLE 87. AMERICAS PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 88. AMERICAS PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 89. AMERICAS PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 90. AMERICAS PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 91. AMERICAS PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 92. AMERICAS PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 93. AMERICAS PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 94. AMERICAS PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 95. AMERICAS PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
TABLE 96. AMERICAS PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DOSAGE STRENGTH, 2025-2030 (USD MILLION)
TABLE 97. AMERICAS PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 98. AMERICAS PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 99. UNITED STATES PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2018-2024 (USD MILLION)
TABLE 100. UNITED STATES PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2025-2030 (USD MILLION)
TABLE 101. UNITED STATES PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY COMPLEMENT INHIBITORS, 2018-2024 (USD MILLION)
TABLE 102. UNITED STATES PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY COMPLEMENT INHIBITORS, 2025-2030 (USD MILLION)
TABLE 103. UNITED STATES PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY GENE THERAPIES, 2018-2024 (USD MILLION)
TABLE 104. UNITED STATES PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY GENE THERAPIES, 2025-2030 (USD MILLION)
TABLE 105. UNITED STATES PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPIES, 2018-2024 (USD MILLION)
TABLE 106. UNITED STATES PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPIES, 2025-2030 (USD MILLION)
TABLE 107. UNITED STATES PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY ADMINISTRATION FREQUENCY, 2018-2024 (USD MILLION)
TABLE 108. UNITED STATES PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY ADMINISTRATION FREQUENCY, 2025-2030 (USD MILLION)
TABLE 109. UNITED STATES PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 110. UNITED STATES PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 111. UNITED STATES PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 112. UNITED STATES PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 113. UNITED STATES PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 114. UNITED STATES PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 115. UNITED STATES PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 116. UNITED STATES PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 117. UNITED STATES PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
TABLE 118. UNITED STATES PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DOSAGE STRENGTH, 2025-2030 (USD MILLION)
TABLE 119. UNITED STATES PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 120. UNITED STATES PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 121. CANADA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2018-2024 (USD MILLION)
TABLE 122. CANADA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2025-2030 (USD MILLION)
TABLE 123. CANADA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY COMPLEMENT INHIBITORS, 2018-2024 (USD MILLION)
TABLE 124. CANADA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY COMPLEMENT INHIBITORS, 2025-2030 (USD MILLION)
TABLE 125. CANADA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY GENE THERAPIES, 2018-2024 (USD MILLION)
TABLE 126. CANADA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY GENE THERAPIES, 2025-2030 (USD MILLION)
TABLE 127. CANADA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPIES, 2018-2024 (USD MILLION)
TABLE 128. CANADA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPIES, 2025-2030 (USD MILLION)
TABLE 129. CANADA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY ADMINISTRATION FREQUENCY, 2018-2024 (USD MILLION)
TABLE 130. CANADA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY ADMINISTRATION FREQUENCY, 2025-2030 (USD MILLION)
TABLE 131. CANADA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 132. CANADA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 133. CANADA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 134. CANADA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 135. CANADA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 136. CANADA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 137. CANADA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 138. CANADA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 139. CANADA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
TABLE 140. CANADA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DOSAGE STRENGTH, 2025-2030 (USD MILLION)
TABLE 141. MEXICO PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2018-2024 (USD MILLION)
TABLE 142. MEXICO PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2025-2030 (USD MILLION)
TABLE 143. MEXICO PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY COMPLEMENT INHIBITORS, 2018-2024 (USD MILLION)
TABLE 144. MEXICO PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY COMPLEMENT INHIBITORS, 2025-2030 (USD MILLION)
TABLE 145. MEXICO PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY GENE THERAPIES, 2018-2024 (USD MILLION)
TABLE 146. MEXICO PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY GENE THERAPIES, 2025-2030 (USD MILLION)
TABLE 147. MEXICO PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPIES, 2018-2024 (USD MILLION)
TABLE 148. MEXICO PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPIES, 2025-2030 (USD MILLION)
TABLE 149. MEXICO PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY ADMINISTRATION FREQUENCY, 2018-2024 (USD MILLION)
TABLE 150. MEXICO PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY ADMINISTRATION FREQUENCY, 2025-2030 (USD MILLION)
TABLE 151. MEXICO PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 152. MEXICO PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 153. MEXICO PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 154. MEXICO PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 155. MEXICO PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 156. MEXICO PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 157. MEXICO PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 158. MEXICO PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 159. MEXICO PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
TABLE 160. MEXICO PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DOSAGE STRENGTH, 2025-2030 (USD MILLION)
TABLE 161. BRAZIL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2018-2024 (USD MILLION)
TABLE 162. BRAZIL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2025-2030 (USD MILLION)
TABLE 163. BRAZIL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY COMPLEMENT INHIBITORS, 2018-2024 (USD MILLION)
TABLE 164. BRAZIL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY COMPLEMENT INHIBITORS, 2025-2030 (USD MILLION)
TABLE 165. BRAZIL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY GENE THERAPIES, 2018-2024 (USD MILLION)
TABLE 166. BRAZIL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY GENE THERAPIES, 2025-2030 (USD MILLION)
TABLE 167. BRAZIL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPIES, 2018-2024 (USD MILLION)
TABLE 168. BRAZIL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPIES, 2025-2030 (USD MILLION)
TABLE 169. BRAZIL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY ADMINISTRATION FREQUENCY, 2018-2024 (USD MILLION)
TABLE 170. BRAZIL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY ADMINISTRATION FREQUENCY, 2025-2030 (USD MILLION)
TABLE 171. BRAZIL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 172. BRAZIL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 173. BRAZIL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 174. BRAZIL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 175. BRAZIL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 176. BRAZIL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 177. BRAZIL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 178. BRAZIL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 179. BRAZIL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
TABLE 180. BRAZIL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DOSAGE STRENGTH, 2025-2030 (USD MILLION)
TABLE 181. ARGENTINA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2018-2024 (USD MILLION)
TABLE 182. ARGENTINA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2025-2030 (USD MILLION)
TABLE 183. ARGENTINA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY COMPLEMENT INHIBITORS, 2018-2024 (USD MILLION)
TABLE 184. ARGENTINA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY COMPLEMENT INHIBITORS, 2025-2030 (USD MILLION)
TABLE 185. ARGENTINA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY GENE THERAPIES, 2018-2024 (USD MILLION)
TABLE 186. ARGENTINA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY GENE THERAPIES, 2025-2030 (USD MILLION)
TABLE 187. ARGENTINA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPIES, 2018-2024 (USD MILLION)
TABLE 188. ARGENTINA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPIES, 2025-2030 (USD MILLION)
TABLE 189. ARGENTINA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY ADMINISTRATION FREQUENCY, 2018-2024 (USD MILLION)
TABLE 190. ARGENTINA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY ADMINISTRATION FREQUENCY, 2025-2030 (USD MILLION)
TABLE 191. ARGENTINA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 192. ARGENTINA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 193. ARGENTINA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 194. ARGENTINA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 195. ARGENTINA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 196. ARGENTINA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 197. ARGENTINA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 198. ARGENTINA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 199. ARGENTINA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
TABLE 200. ARGENTINA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DOSAGE STRENGTH, 2025-2030 (USD MILLION)
TABLE 201. EUROPE, MIDDLE EAST & AFRICA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2018-2024 (USD MILLION)
TABLE 202. EUROPE, MIDDLE EAST & AFRICA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2025-2030 (USD MILLION)
TABLE 203. EUROPE, MIDDLE EAST & AFRICA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY COMPLEMENT INHIBITORS, 2018-2024 (USD MILLION)
TABLE 204. EUROPE, MIDDLE EAST & AFRICA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY COMPLEMENT INHIBITORS, 2025-2030 (USD MILLION)
TABLE 205. EUROPE, MIDDLE EAST & AFRICA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY GENE THERAPIES, 2018-2024 (USD MILLION)
TABLE 206. EUROPE, MIDDLE EAST & AFRICA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY GENE THERAPIES, 2025-2030 (USD MILLION)
TABLE 207. EUROPE, MIDDLE EAST & AFRICA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPIES, 2018-2024 (USD MILLION)
TABLE 208. EUROPE, MIDDLE EAST & AFRICA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPIES, 2025-2030 (USD MILLION)
TABLE 209. EUROPE, MIDDLE EAST & AFRICA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY ADMINISTRATION FREQUENCY, 2018-2024 (USD MILLION)
TABLE 210. EUROPE, MIDDLE EAST & AFRICA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY ADMINISTRATION FREQUENCY, 2025-2030 (USD MILLION)
TABLE 211. EUROPE, MIDDLE EAST & AFRICA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 212. EUROPE, MIDDLE EAST & AFRICA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 213. EUROPE, MIDDLE EAST & AFRICA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 214. EUROPE, MIDDLE EAST & AFRICA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 215. EUROPE, MIDDLE EAST & AFRICA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 216. EUROPE, MIDDLE EAST & AFRICA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 217. EUROPE, MIDDLE EAST & AFRICA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 218. EUROPE, MIDDLE EAST & AFRICA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 219. EUROPE, MIDDLE EAST & AFRICA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
TABLE 220. EUROPE, MIDDLE EAST & AFRICA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DOSAGE STRENGTH, 2025-2030 (USD MILLION)
TABLE 221. EUROPE, MIDDLE EAST & AFRICA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 222. EUROPE, MIDDLE EAST & AFRICA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 223. UNITED KINGDOM PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2018-2024 (USD MILLION)
TABLE 224. UNITED KINGDOM PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2025-2030 (USD MILLION)
TABLE 225. UNITED KINGDOM PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY COMPLEMENT INHIBITORS, 2018-2024 (USD MILLION)
TABLE 226. UNITED KINGDOM PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY COMPLEMENT INHIBITORS, 2025-2030 (USD MILLION)
TABLE 227. UNITED KINGDOM PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY GENE THERAPIES, 2018-2024 (USD MILLION)
TABLE 228. UNITED KINGDOM PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY GENE THERAPIES, 2025-2030 (USD MILLION)
TABLE 229. UNITED KINGDOM PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPIES, 2018-2024 (USD MILLION)
TABLE 230. UNITED KINGDOM PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPIES, 2025-2030 (USD MILLION)
TABLE 231. UNITED KINGDOM PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY ADMINISTRATION FREQUENCY, 2018-2024 (USD MILLION)
TABLE 232. UNITED KINGDOM PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY ADMINISTRATION FREQUENCY, 2025-2030 (USD MILLION)
TABLE 233. UNITED KINGDOM PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 234. UNITED KINGDOM PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 235. UNITED KINGDOM PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 236. UNITED KINGDOM PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 237. UNITED KINGDOM PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 238. UNITED KINGDOM PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 239. UNITED KINGDOM PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 240. UNITED KINGDOM PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 241. UNITED KINGDOM PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
TABLE 242. UNITED KINGDOM PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DOSAGE STRENGTH, 2025-2030 (USD MILLION)
TABLE 243. GERMANY PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2018-2024 (USD MILLION)
TABLE 244. GERMANY PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2025-2030 (USD MILLION)
TABLE 245. GERMANY PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY COMPLEMENT INHIBITORS, 2018-2024 (USD MILLION)
TABLE 246. GERMANY PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY COMPLEMENT INHIBITORS, 2025-2030 (USD MILLION)
TABLE 247. GERMANY PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY GENE THERAPIES, 2018-2024 (USD MILLION)
TABLE 248. GERMANY PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY GENE THERAPIES, 2025-2030 (USD MILLION)
TABLE 249. GERMANY PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPIES, 2018-2024 (USD MILLION)
TABLE 250. GERMANY PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPIES, 2025-2030 (USD MILLION)
TABLE 251. GERMANY PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY ADMINISTRATION FREQUENCY, 2018-2024 (USD MILLION)
TABLE 252. GERMANY PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY ADMINISTRATION FREQUENCY, 2025-2030 (USD MILLION)
TABLE 253. GERMANY PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 254. GERMANY PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 255. GERMANY PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 256. GERMANY PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 257. GERMANY PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 258. GERMANY PAROXYSMAL

Samples

Loading
LOADING...

Companies Mentioned

  • AstraZeneca plc
  • Apellis Pharmaceuticals, Inc.
  • Swedish Orphan Biovitrum AB
  • Novartis AG
  • Genentech, Inc.
  • Amgen Inc.
  • F. Hoffmann-La Roche Ltd.

Table Information

Report AttributeDetails
No. of Pages189
PublishedAugust 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 3.89 Billion
Forecasted Market Value ( USD ) by 2030 $ 6.51 Billion
Compound Annual Growth Rate10.9%
Regions CoveredGlobal
No. of Companies Mentioned7

Related Topics

Related Reports

Paroxysmal Nocturnal Hemoglobinuria Drugs Market - Global Forecast 2025-2030 - Product Image

Paroxysmal Nocturnal Hemoglobinuria Drugs Market - Global Forecast 2025-2030

  • Report
  • 185 Pages
  • Global
From
Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment - Global Strategic Business Report - Product Image

Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment - Global Strategic Business Report

  • Report
  • 126 Pages
  • Global
From
Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size, Share & Trends Analysis Report By Treatment, By Region, And Segment Forecasts, 2025 - 2030 - Product Image

Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size, Share & Trends Analysis Report By Treatment, By Region, And Segment Forecasts, 2025 - 2030

  • Report
  • 100 Pages
  • Global
From
Paroxysmal Nocturnal Hemoglobinuria (PNH) Market Report 2025 - Product Image

Paroxysmal Nocturnal Hemoglobinuria (PNH) Market Report 2025

  • Report
  • 200 Pages
  • Global
From
Paroxysmal Nocturnal Hemoglobinuria (PNH) And Atypical Hemolytic Uremic Syndrome (aHUS) Global Market Report 2025 - Product Image

Paroxysmal Nocturnal Hemoglobinuria (PNH) And Atypical Hemolytic Uremic Syndrome (aHUS) Global Market Report 2025

  • Report
  • 175 Pages
  • Global
From

About the Paroxysmal Nocturnal Hemoglobinuria Drug Market

The Paroxysmal Nocturnal Hemoglobinuria (PNH) drug market is a specialized segment within the broader category of hematological drugs, which encompasses medications for a wide range of blood disorders. PNH is a rare, life-threatening blood disease characterized by the destruction of red blood cells, leading to hemoglobin release in the urine, particularly noticeable at night or in the early morning. Treatments for PNH focus on reducing hemolysis, preventing thrombosis, and improving quality of life. Historically, the management of PNH involved supportive treatments such as blood transfusions and iron therapy; however, the advent of novel targeted therapies has transformed the therapeutic landscape. These innovative drugs inhibit the complement system, which plays a central role in the pathophysiology of PNH. The development and approval of these complement inhibitors have provided patients with the first disease-specific treatments, substantially improving clinical outcomes. Several companies have made their mark in the PNH drug market, with a strong focus on research and development for more effective and patient-friendly treatments. Leading players include Alexion Pharmaceuticals, Inc., which developed eculizumab, a monoclonal antibody that has been a cornerstone in PNH treatment. Other notable companies operating in the space are Apellis Pharmaceuticals, which has made strides with its complement inhibitor pegcetacoplan, and Novartis, exploring gene-therapy approaches to provide long-term relief for patients afflicted by the disorder. These companies, along with others engaged in the Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.